

1 **Total serum antioxidant capacity in healthy normal weight and asymptomatic overweight**
2 **adults**

3

4 **Ana Petelin¹, Paola Tedeschi², Annalisa Maietti², Mihaela Jurdana¹, Vincenzo**
5 **Brandolini², Zala Jenko Pražnikar¹**

6 ¹University of Primorska, Faculty of Health Sciences, Izola, Slovenia

7 ²University of Ferrara, Department of Chemical and Pharmaceutical Sciences, Italy

8

9 Ana Petelin, University of Primorska, Faculty of Health Sciences, Polje 42, SI-6310 Izola,
10 Slovenia; ana.petelin@fvz.upr.si

11 Mihaela Jurdana, University of Primorska, Faculty of Health Sciences, Polje 42, SI-6310 Izola,
12 Slovenia; Mihaela.jurdana@fvz.upr.si

13 Paola Tedeschi, University of Ferrara, Department of Chemical and Pharmaceutical Sciences,
14 Ferrara, Italy; paola.tedeschi@unife.it

15 Annalisa Maietti, University of Ferrara, Department of Chemical and Pharmaceutical Sciences,
16 Ferrara, Italy; annalisa.maietti@unife.it

17 Vincenzo Brandolini, University of Ferrara, Department of Chemical and Pharmaceutical
18 Sciences, Ferrara, Italy; Vincenzo.brandolini@unife.it

19

20 **Address correspondence to:** Zala Jenko Pražnikar, University of Primorska, Faculty of Health
21 Sciences, Izola, Polje 42, SI-6310 Izola, Slovenia; Tel: (00386) 05-662-6469; Fax: (00386) 05-
22 662-6480; E-mail: zala.praznikar@fvz.upr.si

23

24

25 **Abstract**

26

27 Obesity and overweight are major contributors to the burden of chronic disease. Both are
28 defined as abnormal or excessive fat accumulation and by increased production of free radicals
29 leading to oxidative stress. The aim of the present study was to evaluate whether overweight
30 and fat accumulation is associated with serum total antioxidant capacity (TAC) in men and
31 women, irrespective of nutritional habits, nutrient intakes, physical activity, smoking, and other
32 confounders, which may be responsible to modifying the association between serum TAC and
33 overweight/obesity measures. This cross-sectional study was conducted on 48 normal weight
34 and 48 overweight adults aged 25-49. All participants underwent standard anthropological
35 measurements of body composition, blood pressure and biochemical measurements, aerobic
36 capabilities assessment and dietary intake evaluation. TAC was measured using
37 photochemiluminescence method. All data were analysed using SPSS software. Men had
38 higher values of TAC than women and concentrations of TAC were significantly higher in
39 overweight subjects compared to normal weight subjects. In the present study TAC tended to
40 be increased with various metabolic risk factors, especially overweight/obesity parameters
41 (body mass index, body fat), inflammation and increased serum levels of Cysteine, irrespective
42 of nutritional habits, nutrient intakes, physical activity and smoking. Overweight and obesity in
43 early stage may stimulate TAC. Therefore, the elevation of TAC in overweight adults may be
44 a compensatory response to oxidative stress, generated by reactive oxygen species.

45

46 **Keywords:** antioxidant capacity, overweight, obesity, oxidative stress, metabolic risk factors,
47 asymptomatic population

48

49 **Introduction**

50

51 Obesity and overweight are chronic disorders of multifactorial origin which can be
52 defined as an increase in the accumulation of body fat (BF) (Fernandez-Sanchez et al. 2011).
53 Obesity is increasing at an alarming rate worldwide and it is known that obesity has a significant
54 impact on mortality and morbidity of people of all ages. Obesity is correlated with systemic
55 inflammation, and accompanied by high-oxidative status (D'Archivio et al. 2012). Therefore,
56 high oxidative status is a principal causative factor in the development of various diseases, such
57 as metabolic syndrome (MetS), dyslipidaemia, atherosclerosis, cardiovascular diseases
58 (CVDs), type-2 diabetes mellitus (T2DM) and others (Freedman et al. 2001; Olusi 2002).

59 Oxidative stress results from redox imbalance, characterized by condition when the
60 production of reactive oxygen species (ROS) compromises the action of endogenous
61 antioxidant system (Wolin 2009). The damage induced by oxidative stress only occurs when
62 the antioxidant defences are unable to counteract the production of ROS; in that occasion it
63 leads to oxidative damage of lipids, proteins and DNA and might have a significant impact on
64 the pathophysiology of obesity-related complications (Martin-Gallan et al. 2007). The human
65 body has developed several mechanisms to protect biomolecules from the deleterious effects of
66 ROS. These include the antioxidant enzymes, such as superoxide dismutase (SOD), catalase
67 (CAT), glutathione reductase and glutathione peroxidase (GSH-Px), as well as water and lipid-
68 soluble antioxidants, such as GSH, ascorbate (vitamin C), α -tocopherol (vitamin E) and β -
69 carotene (Gutierrez-Salinas et al. 2013). The sum of endogenous and food-derived antioxidants
70 represents the total antioxidant capacity (TAC) of extracellular fluids.

71 TAC assessment is an established methodology to measure the overall antioxidant
72 defense system; in recent years, several methods have been proposed to determine the TAC.

73 An increasing number of studies focus on the role of ROS in the pathogenesis of
74 numerous civilization diseases, such as obesity (Karaouzene et al. 2011). It has been suggested
75 that higher antioxidant potential can protect the organism against undesirable ROS activity and
76 thus prevent disease incidence (Briasoulis et al. 2009). However, the present state of knowledge
77 on such dependence is still not complete (Munzel et al. 2010). In addition, the knowledge of
78 the antioxidant potential in asymptomatic, healthy, overweight subjects warrants confirmation,
79 because the previous studies provided confusing results on the relationship of the presence of
80 excess of BF to TAC. TAC has been reported to be higher or lower in different studies (Kim et
81 al. 2000; Bae et al. 2006; Kwak and Soon 2007; Simao et al. 2008; Faienza et al. 2012).

82 Therefore, the aim of the study was to investigate whether overweight, obesity at early
83 stage and fat accumulation is associated with serum TAC in men and women, irrespective of
84 nutritional habits, nutrient intakes, physical activity, smoking, and other confounders, which
85 may be responsible for modifying the association between serum TAC and overweight/obesity
86 measures.

87

88 **Materials and methods**

89

90 **Subjects and Protocol of measures**

91 The initial study population consisted of 182 individuals (70 males and 112 females). Subjects
92 age range from 25 to 49 years old. The subjects were recruited by the use of flyers, internet
93 forums, e-mail, and newspaper advertisements and by personal contact. Sample size (124
94 subjects) was calculated based on the confidence level (95%), confidence interval (5%), on the
95 population size (182 individuals), and on the number of participants in related previous studies.
96 But the final analytical sample was confined to 96 asymptomatic subjects (32 males and 64
97 females). Among the initial subjects, subjects with BMI higher than 35 or lower than 19, taking
98 medications for lipid disorder or taking anti-inflammatory drugs (NSAID), taking nutritional
99 supplements, having CVDs, endocrine and acute or chronic inflammatory disease, T2DM, not
100 completing questionnaires, and more than 3% change of body mass within the last three months
101 were excluded. The final analytical sample was confined to 96 asymptomatic subjects (32 males
102 and 64 females). The study protocol was approved by the Slovenian National Medical Ethics
103 Committee and informed consent was obtained from each study participants. Measurements
104 were performed in standardized conditions: quiet thermally neutral environment (20 to 22°C),
105 overnight fast (at least 12 h from the last meal and drink consumption (except from water), 12
106 h without physical exercise and smoking, empty bladder.

107

108 **Dietary and lifestyle assessment**

109 Participant's nutritional intake was assessed by analysis of written food records as described
110 previously (Jenko-Pražnikar et al. 2013). Briefly, all subjects enrolled in the study were
111 instructed to record their daily dietary intake for three days, including a weekend day Records
112 were reviewed by a trained dietitian and analyzed using a web application for analysis of food

|

113 diary, named OPEN (Open Platform for Clinical Nutrition), accessible through the web site
114 http://www.opkp.si/en_GB/cms/vstopna-stran. Hand-held indirect calorimeter MedGem®
115 (Medical Home Solutions, Inc., Golden, CO, Microlife) was used for measuring resting
116 metabolic rate (RMR) in standardized conditions and 10 min rest prior the measurements.
117 Fitness index (FI) was assessed to predict maximal oxygen uptake and to measure the ability of
118 brisk walking. The ability to perform high intensity walking on 2 km was measured. The
119 walking time was recorded; the pulse rate was measured at the cervical aorta for 15 s and
120 multiplied by 4. The FI was calculated on the base on the UKK walk test program developed
121 by the UKK Institute for health promotion research, Tampere, Finland, accessible through the
122 website <http://www.ukkinstituutti.fi>. Gender-specific FI was calculated based on age (A), BMI,
123 walking time (T; in minutes, seconds) and pulse (P): for males: $[I= 420 + A*0.2 - T*11.6 -$
124 $P*0.56 - BMI*2.6]$ and for females: $[I= 304 + A*0.4 - T*8.5 - P*0.32 - BMI*1.1]$. The
125 interpretation of FI measurements is: 1) FI < 70 significantly low; 2) FI 70-89 under average;
126 3) FI 90-100 average; 4) FI 111-130 above average; and 5) FI > 130 significantly high according
127 to the UKK walk test program.

128 The Physical questionnaire AMA accessible through the web site (<http://www.ama-assn.org>)
129 was used to assess the general information of physical activity (time spent performing physical
130 activity (number of sessions and average time per session), sedentary pursuits; essentially
131 sitting, and physical activity barriers). The questionnaire was created and funded by the
132 American medical association and the Robert Wood Johnson foundation in November 2003.
133 The whole questionnaire is accessible through the website:
134 <http://www.afhaz.com/images/obesityamaphysicalacitvity.pdf>

135

136 **Anthropometric measurements**

137 All measurements were carried out following an overnight fast by the same examiner. Subject
138 height was measured to the nearest 0.1 cm in a standing position, without shoes, using
139 stadiometer Leicester Height Measure (Invicta Plastics Limited, Oadby, England). Participant
140 were asked to stand on the stadiometer, facing forwards and straight as possible with their arms
141 hanging loosely at their sides. Their feet were flat on the base plate of the stadiometer and
142 positioned slightly apart, in line with their hips, to aid balance. Their knees were straight and
143 their buttocks and shoulders touched the stadiometer. The participant's head was in the
144 "Frankfort plane". Body weight of the participants wearing usual light indoor clothing without
145 shoes and standing in a stable position without bending their knees and standing motionless
146 with their arms at their sides was measured with a 0.1 kg precision by using bioelectrical
147 impedance analysis (BIA) Tanita BC 418MA (Tanita Corporation, Arlington Heights, IL) and
148 data analyzed with the software provided by the same producer. Waist circumference (WC) was
149 measured midway between the lowest rib and the iliac crest with the subjects in a standing
150 position. Hip circumference (HC) was measured as the maximum circumference around the
151 buttocks. Body mass index (BMI) was calculated as $\text{weight}/\text{height}^2$ (kg/m^2). Body composition
152 (total percentage body fat (% BF) and percentage trunk fat (% TF)) was assessed using
153 bioelectrical impedance analysis (BIA) Tanita BC 418MA (Tanita Corporation, Arlington
154 Heights, IL) and data analyzed with the software provided by the same producer. Overweight
155 was defined by $25 < \text{BMI} < 30 \text{ kg}/\text{m}^2$ and obesity by two of the following $\text{BMI} \geq 30 \text{ kg}/\text{m}^2$, WC
156 $\geq 94 \text{ cm}$ for male and $\geq 80 \text{ cm}$ for female and/or $\% \text{ BF} \geq 21.5$ for male and ≥ 32 for female. In
157 male group 16 % were obese, 34 % were overweight and 50 % were normal weight. Similarly,
158 in female group 17 % were obese, 33 % were overweight and 50 % were normal weight.
159 Systolic and diastolic blood pressure was monitored in the left arm. MetS was defined as having
160 ≥ 3 of criteria based on the Harmonization definition (Alberti et al. 2009).

161

162 Total antioxidant capacity (TAC)

163 The antioxidant capacity of serum samples was measured by Photochem[®] instrument (Analytic
164 Jena, Jena, Germany) using ACW kits (Water Antioxidant Capacity) to detect the activity of
165 hydrophilic compounds. The ultra-sensitive PCL assay was carried out with the procedure
166 described by Popov and Lewin (1999). 1.5 mL of reagent 1 (solvent and dilution reagent), 1
167 mL of reagent 2 (buffer solution), 25 μ L of reagent 3 (photosensitizer), and 0 to 30 μ L of
168 standard (ascorbic acid) or 10 μ L sample (diluted serum) solution were mixed and measured.
169 In ACW studies, the presence of ascorbic acid or any other antioxidants from the extracts,
170 retarded luminescence for a period; hence, a lag time was noted before a signal was measured.
171 The duration of the lag, calculated by the computer software from the first derivative of the
172 detector signal at its turning point and intersection with the x-axis, was plotted against the
173 concentration of ascorbic acid added to the assay medium. The results were expressed as
174 nanomoles equivalents of ascorbic acid per μ L of serum.

175

176 Laboratory measurements

177 Blood samples were collected after an overnight fast in 4 mL vacuum test tubes (Beckton-
178 Dickinson, Rutherford, USA). The blood samples were centrifuged and the separated serum
179 samples were immediately frozen and stored at -20 °C. Biochemical analyses have been
180 described (Jenko-Pražnikar et al. 2013). The serum interleukin 6 (IL-6) and tumor necrosis
181 factor α (TNF- α) levels were measured in duplicate on microplate reader (Tecan, Männedorf,
182 Switzerland) with an enzyme immunoassay kit for IL-6 and TNF- α (both Thermo Fischer
183 Scientific Inc., Rockford, USA). Assay sensitivity was <1 pg/mL for IL-6 and <2 pg/mL for
184 TNF- α . Serum concentrations of glucose, TAG, total cholesterol, low density lipoprotein (LDL)
185 cholesterol, high density lipoprotein (HDL) cholesterol and C-reactive protein (CRP) were
186 measured with the use of Olympus reagents and performed on an AU 680 analyzer (Beckman

187 Coulter). Serum insulin concentrations was measured with the use of Abbott reagents and
188 performed on a 2000 iSR analyzer (Abbott Architect). The homeostasis model assessment
189 (HOMA) was used as a measure of insulin resistance HOMA-IR. HOMA-IR was calculated
190 according to the following formula: fasting insulin ($\mu\text{U/L}$) x fasting glucose (mmol/L) / 22.5
191 (Matthews et al. 1985).

192 Serum levels of Cysteine (Cys) were analyzed by gas chromatography-mass spectrometry (GC-
193 MS), as previously described (Biolo et al. 20089). Briefly, known amounts of $^2\text{H}_2$ -Cysteine
194 (Cambridge Isotope Laboratories) were used as internal standards. Serum samples (200 μL)
195 with a known amount of added internal standard were treated with sulphosalicylic acid, then
196 centrifuged and purified on a cationic resin (AG50W-X8; Bio-Rad, Hercules, CA). After that,
197 samples were lyophilized and Cys was derivatized by the addition of acetonitrile and
198 MTBSTFA (N-methyl-N- (tert-butyldimethylsilyl)-trifluoroacetamide) and by heating at 90°C
199 for 45 min. After derivatization, samples were injected into a GC-MS system (HP 5890, Agilent
200 Technologies, and Santa Clara, CA, USA). Serum concentrations of Cys had his own internal
201 standard (Cys m/z 406/408).

202

203 **Statistical analysis**

204 Variables are presented as means \pm SD. Descriptive statistics were tested before statistical
205 analysis as being normally distributed; data that was not normally distributed (serum levels of
206 LDL cholesterol, TAG, CRP, insulin, HOMA-IR and $\text{TNF-}\alpha$) was logarithmically transformed
207 for subsequent analysis. In order to investigate the metabolic profile and TAC the subjects were
208 divided in two different groups according to the BMI, WC and body fat (in normal weight or
209 overweight group). Anthropometrical, nutritional, physical characteristics and serum
210 metabolites were compared between two groups using an independent-sample t-test. A chi
211 square (χ^2) was used to investigate whether distributions of categorical variables differ from

212 one another. Pearson's correlation analyses (crude and adjusted for age, physical activity, total
213 energy intake, and common cardio metabolic risk factors (blood pressure, glucose, LDL/HDL-
214 cholesterol, TAG) were performed to detect different associations between serum TAC and
215 anthropometric and biochemical parameters in men and women. SPSS software (IBM SPSS
216 version 19.0, Chicago, IL) was used for all analyses. A *P* value of less than 0.05 was considered
217 statistically significant.

218

219

220 **Results**

221

222 Table 1 present the baseline characteristics of normal weight group and overweight group,
223 separately for females (64 subjects) and males (32 subjects). No significant differences were
224 found between the tested groups with respect to age. The differences were found in
225 anthropometric parameters, i.e. in body weight, BMI, WC and % BF in both sexes. A wide
226 range of lean and overweight subjects were included in our study (Table 1); thus, the % BF
227 ranged from 5 % to 30 % in men, and from 17 % to 45 % in women. Participants of both groups
228 were either normotensive or pre-hypertensive (average SBP < 140 and average DSP < 90). In
229 men, weight, WC, systolic blood pressure and RMR, were found to be significantly higher and
230 values of BF significantly lower when compared with women (data not shown). In addition, the
231 biochemical analyses, fasting insulin, HOMA-IR, TAG, CRP, TNF- α , LDL cholesterol of
232 overweight participants of both sexes were found to be statistically significantly higher when
233 compared to normal weight participants (Table 1). Moreover, male subjects were characterized
234 by significantly higher values of fasting glucose, HOMA-IR, TAG and lower values of HDL-
235 cholesterol, and CRP in comparison with the women (data not shown).

236

237 >> **Table 1**

238

239 Aerobic capabilities of participants were assessed by general fitness level, using calculated FI
240 values from the applied UKK Walk Test. No significant differences were found in FI between
241 female and male groups. However, overweight subjects obtained statistically significantly
242 lower values for the aerobic times, meaning they had lower aerobic fitness levels compared to
243 the normal weight subjects. In particular, normal weight participants were in the range of
244 average fitness level (average male FI was 101 ± 13 , and average female FI was 111 ± 15),

|

245 while overweight participants were classified as below average (average male FI was 82 ± 18 ,
246 and average female FI was 83 ± 15) (Table 1). Moreover, there were also some differences in
247 nutrient intake between men and women; significantly higher intake of proteins and fatty acids
248 were found in men than in women (data not shown). On the other hand, there were no significant
249 differences in nutrient intakes between normal and overweight groups (Table 1). Moreover, in
250 the normal weight group we found four underreporters, while in the overweight group we found
251 nine underreporters, where energy intake was less than $0.96 \times \text{RMR}$. However, overweight male
252 and female participants consumed more meat and meat products and less vegetable than normal
253 weight male and female participants (Table 2).

254

255 >> **Table 2**

256

257 Measured serum TAC levels in our study, expressed as nanomoles of ascorbic acids per μL of
258 serum, were lower in the normal weight group in comparison to the overweight participants, in
259 both men and women (Fig. 1). In addition, the TAC was significantly higher in men in
260 comparison to the women (Fig. 1).

261

262 >> **Fig. 1**

263

264 Pearson's correlation analyses were performed to investigate the possible associations between
265 serum TAC levels and the studied parameters (Table 3). Age was not a determinant affecting
266 the antioxidative barrier, regardless of the gender. In both studied groups, TAC was positively
267 related to several anthropometric overweight/obesity measures BMI, BF and WC (Table 3, Fig.
268 2). Positive correlations were observed between serum TAC levels and fasting serum
269 triacylglycerols and CRP in women; on the other hand positive correlations between serum

270 TAC levels and fasting serum glucose, insulin, HOMA-IR and amino acid Cys were found in
271 men (Table 3).

272

273 >> **Table 3**

274

275 >> **Fig. 2**

276

277 Partial correlation analysis were performed between TAC and obesity measures to investigate
278 whether obesity and fat accumulation is associated with serum TAC in men and women,
279 irrespective of nutritional habits, nutrient intakes, physical activity, smoking, and other
280 confounders, which may be responsible to modifying the association between serum TAC and
281 overweight/obesity measures. Adjustments included age, physical activity, total energy intake,
282 blood pressure, fasting glucose, LDL/HDL-cholesterol and TAG in men and women. Indeed,
283 in both groups TAC was positively related to BMI and BF, irrespective of mentioned
284 confounders. In addition, positive association remained significant between TAC and CRP after
285 adjustments in female subjects and between TAC and Cys in male subjects (Table 4).

286

287 >> **Table 4**

288

289 **Discussion**

290 In the present study, the PCL assay was performed according to measures the total
291 antioxidant capacity of all antioxidants present in serum. In this study, we showed that
292 overweight asymptomatic, i.e. apparently healthy, individuals have higher serum levels of TAC
293 than normal weight controls. The most likely explanation for our observations is that body
294 responded to increased oxidative stress accompanying overweight/obesity by increasing TAC.
295 Moreover, this phenomenon was evident in both men and women.

296 In the present study TAC tended to be higher with various metabolic risk factors,
297 especially overweight/obesity parameters, inflammation and increased serum levels of Cys.
298 TAC was significantly positively related with increased weight, BMI, waist circumference, BF
299 and was significantly higher in healthy overweight subjects. Obesity has shown to increase
300 oxidative stress by increased LDL oxidation and malondialdehyde (MDA), and these markers
301 of oxidative stress have found to be related with BMI and waist to hip ratio (Mohn et al. 2007).
302 In addition, growing evidence indicates that the mitochondria of white adipose tissue,
303 particularly of obese persons, are the main site of ROS generation, accompanied by decreased
304 expression of antioxidative enzymes (Roberts et al. 2006). However, TAC measured with
305 various methods has not seemed to decrease in overweight and obese people (Kim et al. 2000;
306 Molnar et al. 2004; Bae 2006). Similar to the findings from the present study, TAC was
307 significantly higher in overweight adult males (Kim et al. 2000) and tended to be, but not
308 significantly, higher in obese children (Molnar et al. 2004), as compared to controls. In addition,
309 TAC was found to be significantly positively correlated with weight and BMI in 158 adults
310 with and without hypertension (Kim et al. 2006). These findings, including the results from the
311 present study, consistently suggest that weight gain may increase serum or plasma TAC.

312 Emerging evidence shows that metabolically benign overweight individuals have a
313 greater subclinical cardiovascular disease burden than those of normal weight (Khan et al.

2011), and also that cardiovascular diseases are correlated with oxidative stress-generating conditions (Schnabel and Blankenberg 2007; Lear et al. 2012). In previous studies, obesity has often been accompanied with increased serum glucose, TAG and total cholesterol (Ahn et al. 2005). In conjunction with obesity, serum glucose and insulin significantly positively correlated with TAC in male subjects, while serum TAG significantly positively correlated with TAC in female subjects. However, the findings in the association between TAC and increased glucose, TAG and/or total cholesterol in various metabolic conditions have shown to vary (Kural et al. 2003; Kural et al. 2004). Based on these finding, it is possible to justify that in the present study, the highest serum TAC was associated with higher TAG circulating levels. In addition, obesity is also associated with a chronic state of low-grade inflammation, which can further drive oxidative stress (Wisse 2004; Sun et al. 2012). Indeed, in the present study positive association between CRP and TAC were found, considering the increase in serum TAC as a compensatory system with the purpose of restoring homeostatic balance.

We observed substantially higher levels of Cys in overweight asymptomatic population. High plasma Cys showed to be linked to obesity – Cys might even cause obesity and have an insulin-like action on adipocytes (Elshorbagy et al. 2012). Total Cys showed to have strong positive correlation with fat mass and to be a stronger predictor of fat mass than serum lipids such as TAG, HDL, and total cholesterol (Elshorbagy et al. 2008). Serum Cys imbalances therefore correlate with markers of metabolic dysfunction. We found significant positive correlations between serum Cys and HOMA-IR, CRP, TNF- α , WC and a body shape index in recent work (Mohorko et al. 2015), and here we presented significant positive correlation between Cys and TAC. Cys is involved in body's antioxidant defense as one of the amino acids involved in synthesis of glutathione (GSH), together with glutamate and glycine (Wu et al. 2004).

338 In physiological conditions, a great part of TAC appears to be due to the endogenous
339 component activity (Crews et al. 2001); however, many studies report the ability of the dietary
340 intake to modulate antioxidant status after the acute consumption of antioxidant rich foods
341 (Hassimotto et al. 2008; Potter et al. 2011). In our study, both caloric intake and nutrient intake
342 and foods habits were quite similar between normal and overweight participants; however,
343 normal weight subjects consumed more vegetables and less meat products per day than
344 overweight subjects and at the same time had lower TAC. It is possible that overweight subjects
345 responded through an inflammatory reaction to high fat meat diet, accompanied by an increased
346 production of the endogenous antioxidants. Indeed, between normal and overweight groups
347 were significant differences in meat and meat products intake.

348 Moreover, there are some other confounders influencing serum levels of TAC. Increased
349 physical activity is known to be negatively correlated with the MetS (Larsson et al. 2012), and
350 a better FI level means a better antioxidant protective mechanism (Atalay and Sen 1999).
351 Physical activity has an important role to increase the TAC in healthy human blood after a
352 single bout of exercise maximal or submaximal. This reinforcement of the antioxidant system
353 due to training may be explained by the fact that exercise stimulates the expression of the genes
354 (mainly NF- κ B) involved in the regulation of the antioxidant enzymes in redox sensitive signal
355 transduction pathways (Berzosa et al. 2011). However, in the present study normal weight
356 subjects with lower TAC, were more physically active and had higher FI. Similar was shown
357 in the study of Gawron-Skarbek et al. (2015), who found that the serum total antioxidant
358 capacity is inversely correlated with fitness characteristics in men with coronary heart disease.
359 The authors concluded that uric acid, the main determinant of serum TAC, may be partially
360 responsible for those associations (Gawron-skarbek et al. 2015). Therefore, the increased TAC
361 levels in the overweight subjects of our study might be related with the uric acid level, especially
362 since a higher consumption of meat and meat products were found in this group.

363 In the current study, TAC was significantly positively associated with obesity measures,
364 as well as number of metabolic risk factors, although these conditions have known to be high
365 in oxidative stress. Therefore, it seems that TAC appears to be affected by changes in individual
366 antioxidant parameters which might be altered by various metabolic conditions. These
367 antioxidant parameters affecting TAC values could be increased not only by body's increased
368 antioxidant status, but by body's compensatory mechanism to counteract increased oxidative
369 stress (Ames et al. 1985). Indeed, in obese subjects, higher levels of RO metabolites were found
370 (Vassalle et al. 2013). It means that overweight/obesity may stimulate TAC and high values of
371 antioxidant potential among overweight/obese individuals may be explained by secondary
372 response to intensified oxidative stress characterizing subjects with higher amount of adipose
373 tissue (Keaney et al. 2003). Adipose tissue in general possesses relatively high levels of
374 antioxidant defensive enzymes for managing high ROS production (Yang et al. 2008).
375 Therefore, in early stages of metabolic disorders, but already in the presence of risk factors
376 (overweight/obesity, elevated blood pressure, lipids,...), the antioxidant defence system may
377 respond to sustained oxidative stress by increasing its activity, but by the advanced stage the
378 balance between generation of free radicals and antioxidant defence is probably impaired as a
379 result of decreased antioxidant levels or activity. Studies have reported low levels of antioxidant
380 enzymes in obese individuals (Sharma and Sharma 2007; Waggiallah and Alzohairy 2011).

381 The present findings are concordant with prior reports on obese humans and animal
382 models which found that in the early stages of obesity development there may be an initial
383 elevation in antioxidant enzymes to counteract oxidative stress (Woo et al. 2012; Gawron-
384 Skarbek et al. 2014).

385 There are several limitations to our study that should be mentioned. It included relatively
386 small numbers of participants, 48 were normal weight and 48 were overweight and obese (obese
387 and overweight subjects were merged in one group, because BMI of our participants was

388 between 26 and 31). However, we are aware that these participants could be metabolically
389 different. Moreover, our study is a cross-sectional study and warrants confirmation through a
390 future prospective study. Since there are no individual antioxidant data available in the present
391 study, we may not be able to strongly assume the factors directly affecting TAC in subjects
392 with and without metabolic risk factors. However, it is worthy to note that positive associations
393 between TAC and increased metabolic risk factors, especially obesity related parameters, were
394 consistently found in the present study and a few previous studies. This implies that increased
395 TAC may not always represent one's healthier condition or condition with a low oxidative
396 stress, suggesting that TAC may not be used as a sole indicator of oxidative stress marker.
397 Further, it is necessary to clarify the unknown factors affecting TAC with relation to various
398 metabolic conditions.

399

400 **Acknowledgments**

401 The authors would like to thank all the subjects for volunteering in this study. This work was
402 supported by the University of Primorska, Faculty of Health Sciences, for the project entitled
403 “A multidisciplinary approach in the treatment of obesity”, by the Slovenian Research Agency
404 (Programme P1-0386), and by the European Regional Development Fund, Cross-Border
405 Cooperation Italy-Slovenia Programme 2007-2013 (EU strategic project TRANS2CARE).

406

407 **Disclosure statement**

408 The authors have no conflicts of interest to report.

409 **References:**

410

411 Ahn, N.Y., Shin, Y.J., Kim, K.J. 2005. Blood lipids concentration and body composition as the
412 different age in obese women. *Journal of Korean Physical Education Association for Girls and*
413 *Women.* **19**: 55–65.

414

415 Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al.
416 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International
417 Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and
418 Blood Institute; American Heart Association; World Heart Federation; International
419 Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation.*
420 **120**(16): 1640-1645.

421

422 Ames, B.N., Cathcart, R., Schwiers, E., Hochstein, P. 1985. Uric acid provides an antioxidant
423 defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. *Proc.*
424 *Natl. Acad. Sci. USA.* **78**(11): 6858–6862.

425

426 Atalay, M., Sen, C.K. 1999. Physical exercise and antioxidant defenses in the heart. *Ann. N. Y.*
427 *Acad. Sci.* **874**: 169-177.

428

429 Bae, H.S. 2006. Body mass index, dietary intake, serum lipids and antioxidant status if young
430 females. *Korean J. Community Nutr.* **11**(4): 479–487.

431

432 Berzosa, C., Cebrián, I., Fuentes-Broto, L., Gómez-Trullén, E., Piedrafita, E., Martínez-
433 Ballarín, E., et al. 2011. Acute exercise increases plasma total antioxidant status and antioxidant
434 enzyme activities in untrained men. *J. Biomed. Biotechnol.* 2011;540458
435 <http://dx.doi.org/10.1155/2011/540458>.

|

- 436
- 437 Biolo, G., Agostini, F., Simunic, B., Sturma, M., Torelli, L., Preiser, J.C., et al. 2008. Positive
438 energy balance is associated with accelerated muscle atrophy and increased erythrocyte
439 glutathione turnover during 5 wk of bed rest. *Am. J. Clin. Nutr.* **88**(4): 950-958.
- 440
- 441 Briasoulis, A., Tousoulis, D., Antoniadis, C., Stefanadis, C. 2009. The oxidative stress menace
442 to coronary vasculature: any place for antioxidants? *Curr. Pharm. Des.* **15**(26): 3078-3090.
- 443
- 444 Crews, H., Alink, G., Andersen, R., Braesco, V., Holst, B., Maiani, G., et al. 2001. A critical
445 assessment of some biomarker approaches linked with dietary intake. *Br. J. Nutr.* **86**:Suppl
446 1:S5-35.
- 447
- 448 D'Archivio, M., Annuzzi, G., Vari, R., Filesi, C., Giacco, R., Scazzocchio, B., et al. 2012.
449 Predominant role of obesity/insulin resistance in oxidative stress development. *Eur. J. Clin.*
450 *Invest.* **42**(1): 70-78.
- 451
- 452 Elshorbagy, A.K., Nurk, E., Gjesdal, C.G., Tell, G.S., Ueland, P.M., Nygård, O., et al. 2008.
453 HomoCysteine, Cysteine, and body composition in the Hordaland HomoCysteine Study: does
454 Cysteine link amino acid and lipid metabolism. *Am. J. Clin. Nutr.* **88**(3): 738-746.
- 455
- 456 Elshorbagy, A.K., Smith, A.D., Kozich, V., Refsum, H. 2012. Cysteine and obesity. *Obesity.*
457 **20**(3): 473-481.
- 458 Faienza, M.F., Francavilla, R., Goffredo, R., Ventura, A., Marzano, F., Panzarino, G., et al.
459 2012. Oxidative Stress in Obesity and Metabolic Syndrome in Children and Adolescents. *Horm.*
460 *Res. Paediatr.* **78**(3): 158–164.
- |

461
462 Fernández-Sánchez, A., Madrigal-Santillán, E., Bautista, M., Esquivel-Soto, J., Morales-
463 González, A., Esquivel-Chirino, C., et al. 2011. Inflammation, oxidative stress, and obesity. *Int.*
464 *J. Mol. Sci.* **12**(5): 3117-3132.

465
466 Freedman, D.S., Khan, L.K., Dietz, W.H., Srinivasan, S.R., Berenson, G.S. 2001. Relationship
467 of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart
468 Study. *Pediatrics.* **108**(3): 712–718.

469
470 Gawron-Skarbek, A., Chrzczanowicz, J., Kostka, J., Nowak, D., Drygas, W., Jegier, A., et al.
471 2014. Cardiovascular risk factors and total serum antioxidant capacity in healthy men and in
472 men with coronary heart disease. *Biomed Res Int.* 2014:216964.

473
474 Gawron-Skarbek, A., Chrzczanowicz, J., Kostka, J., Nowak, D., Drygas, W., Jegier, A., et al.
475 2015. Physical Activity, Aerobic Capacity, and Total Antioxidant Capacity in Healthy Men
476 and in Men with Coronary Heart Disease. *Oxid Med Cell Longev.* 2015:197307. doi:
477 10.1155/2015/197307.

478
479 Gutiérrez-Salinas, J., García-Ortíz, L., Morales González, J.A., Hernández-Rodríguez, S.,
480 Ramírez-García, S., Núñez-Ramos, N.R., et al. 2013. In vitro effect of sodium fluoride on
481 malondialdehyde concentration and on superoxide dismutase, catalase, and glutathione
482 peroxidase in human erythrocytes. *ScientificWorldJournal.* 2013:864718.

483

484 Hassimotto, N.M., Pinto Mda, S., Lajolo, F.M. 2008. Antioxidant status in humans after
485 consumption of blackberry (*Rubus fruticosus* L.) juices with and without defatted milk. *J.*
486 *Agric. Food. Chem.* **56**(24): 11727-11733.

487

488 Jenko-Pražnikar, Z., Petelin, A., Jurdana, M., Žiberna, L. 2013. Serum bilirubin levels are lower
489 in overweight asymptomatic middle-aged adults: An early indicator of metabolic syndrome?
490 *Metabolism.* **62**(7): 976-985.

491

492 Karaouzene, N., Merzouk, H., Aribi, M., Merzouk, S.A., Berrouiguet, A.Y., Tessier, C., et al.
493 2011. Effects of the association of aging and obesity on lipids, lipoproteins and oxidative stress
494 biomarkers: a comparison of older with young men. *Nutr. Metab. Cardiovasc. Dis.* **21**(10): 792–
495 799.

496

497 Khan, U.I., Wang, D., Thurston, R.C., Sowers, M., Sutton-Tyrrell, K., Matthews, K.A., et al.
498 2011. Burden of subclinical cardiovascular disease in "metabolically benign" and "at-risk"
499 overweight and obese women: the Study of Women's Health Across the Nation (SWAN).
500 *Atherosclerosis.* **217**(1): 179-186.

501

502 Keaney, J.F. Jr, Larson, M.G., Vasani, R.S., Wilson, P.W., Lipinska, I., Corey, D., et al. 2003.
503 Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham
504 Study. *Arterioscler Thromb Vasc Biol.* **23**(3): 434-439.

505

506 Kim, S.K., Park, Y.S., Byoun, K.E. 2000. Comparison of the total antioxidant status and usual
507 dietary intake in normal and overweight males. *Korean J. Community Nutr.* **5**(4): 633-641.

508

|

- 509 Kim, J.H., Kim, M.J., Kwak, H.K. 2006. Obesity indices and plasma total antioxidant status in
510 hypertensive elderly living in Ulsan area. *Korean J. Community Nutr.* **11**(2): 279-288.
511
- 512 Kural, B.V., Orem, A., Cimsit, G., Yandi, Y.E., Calapoglu, M. 2003. Evaluation of the
513 atherogenic tendency of lipids and lipoprotein content and their relationship with oxidant-
514 antioxidant system in patients with psoriasis. *Clin. Chim. Acta.* **328**(1-2): 71-82.
515
- 516 Kural, B.V., Orem, C., Uydu, H.A., Alver, A., Orem, A. 2004. The effects of lipid-lowering
517 therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in
518 patients with dyslipidemia. *Coron. Artery. Dis.* **15**(5): 277-283.
519
- 520 Kwak, H.K., Yoon, S. 2007. Relation of serum total antioxidant status with metabolic risk
521 factors in Korean adults. *Nutr. Res. Pract.* **1**(4): 335-340.
522
- 523 Larsson, C.A., Kroll, L., Bennet, L., Gullberg, B., Rastam, L., Lindblad, U. 2012. Leisure time
524 and occupational physical activity in relation to obesity and insulin resistance: a population-
525 based study from the Skaraborg Project in Sweden. *Metabolism.* **61**(4): 590-598.
526
- 527 Lear, S.A., Sarna, L.K., Siow, T.J., Mancini, G.B., Siow, Y.L., O K. 2012. Oxidative stress is
528 associated with visceral adipose tissue and subclinical atherosclerosis in a healthy multi-
529 ethnic population. *Appl. Physiol. Nutr. Metab.* **37**(6): 1164-1170.
530
- 531 Martín-Gallán, P., Carrascosa, A., Gussinyé, M., Domínguez, C. 2007. Changes in oxidant-
532 antioxidant status in young diabetic patients from clinical onset onwards. *J. Cell. Mol. Med.*
533 **11**(6): 1352–1366.

- 534
- 535 Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C. 1985.
- 536 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma
- 537 glucose and insulin concentrations in man. *Diabetologia*. **28**(7): 412-419.
- 538
- 539 Mohn, A., Catino, M., Capanna, R., Giannini, C., Marcovecchio, M., Chiarelli, F. 2007.
- 540 Increased oxidative stress in prepubertal severely obese children: Effect of a dietary restriction-
- 541 weight loss program. *J. Clin. Endocrinol. Metab.* **90**(5): 2653-2658.
- 542
- 543 Mohorko, N., Petelin, A., Jurdana, M., Biolo, G., Jenko-Pražnikar, Z. 2015. Elevated serum
- 544 levels of cysteine and tyrosine: early biomarkers in asymptomatic adults at increased risk of
- 545 developing metabolic syndrome. *Biomed. Res. Int.* 2015:418681. Doi:10.1155/2015/418681.
- 546
- 547 Molnar, D., Decsi, T., Koletzko, B. 2004. Reduced antioxidant status in obese children with
- 548 multimetabolic syndrome. *Int. J. Obes. Relat. Metab. Disord.* **28**(10): 1197-1202.
- 549
- 550 Münzel, T., Gori, T., Bruno, R.M., Taddei, S. 2010. Is oxidative stress a therapeutic target in
- 551 cardiovascular disease? *Eur. Heart. J.* **31**(22): 2741-2748.
- 552 Olusi, S.O. 2002. Obesity is an independent risk factor for plasma lipid peroxidation and
- 553 depletion of erythrocyte cytoprotective enzymes in humans. *Int. J. Obes. Relat. Metab. Disord.*
- 554 **26**(9): 1159–1164.
- 555
- 556 Popov, I., Lewin, G. 1999. Photochemiluminescent detection of antiradical activity. VI.
- 557 Antioxidant characteristics of human blood plasma, low density lipoprotein, serum albumin and
- 558 amino acids during in vitro oxidation. *Luminescence*. **14**(3): 169–174.
- |

- 559 Potter, A.S., Foroudi, S., Stamatikos, A., Patil, B.S., Deyhim, F. 2011. Drinking carrot juice
560 increases total antioxidant status and decreases lipid peroxidation in adults. *Nutr. J.* **10**:96.
561
- 562 Roberts, C.K., Barnard, R.J., Sindhu, R.K., Jurczak, M., Ehdaie, A., Vaziri, N.D. 2006.
563 Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-
564 induced metabolic syndrome. *Metabolism.* **55**(7): 928–934.
565
- 566 Schnabel, R., Blankenberg, S. 2007. Oxidative stress in cardiovascular disease: successful
567 translation from bench to bedside? *Circulation.* **116**(12): 1338-1340.
568
- 569 Sharma, R., Sharma, A. 2007. Effect of obesity on antioxidant enzymes and type 2 diabetes.
570 *Indian J Clin Biochem.* 22 Suppl: 259–265.
571
- 572 Simão, A.N., Dichi, J.B., Barbosa, D.S., Cecchini, R., Dichi, I. 2008. Influence of uric acid and
573 gamma-glutamyltransferase on total antioxidant capacity and oxidative stress in patients with
574 metabolic syndrome. *Nutrition.* **24**(7-8): 675–681.
- 575 Skalicky, J., Muzakova, V., Kandar, R., Meloun, M., Rousar, T., Palicka, V. 2008. Evaluation
576 of oxidative stress and inflammation in obese adults with metabolic syndrome. *Clin. Chem.*
577 *Lab. Med.* **46**(4): 499–505.
578
- 579 Sun, S., Ji, Y., Kersten, S., Qi, L. 2012. Mechanisms of inflammatory responses in obese
580 adipose tissue. *Ann. Rev. Nutr.* **32**: 261-286.
581

582 Vassalle, C., Vigna, L., Bianchi, S., Maffei, S., Novembrino, C., De Giuseppe, R., et al. 2013.
583 A biomarker of oxidative stress as a nontraditional risk factor in obese subjects. *Biomark Med.*
584 **7**(4): 633-639.

585

586 Waggiallah, H., Alzohairy, M. 2011. The effect of oxidative stress on human red cells
587 glutathione peroxidase, glutathione reductase level, and prevalence of anemia among diabetics.
588 *N. Am. J. Med. Sci.* **3**(7): 344–347.

589

590 Wisse, B.E. 2004. The inflammatory syndrome: the role of adipose tissue cytokines in
591 metabolic disorders linked to obesity. *J. Am. Soc. Nephrol.* **15**(11): 2792-2800.

592

593 Woo, J., Shin, K.O., Yoo, J.H., Park, S., Kang, S. 2012. The effects of detraining on blood
594 adipokines and antioxidant enzyme in Korean overweight children. *Eur. J. Pediatr.* **171**(2): 235–
595 243.

596

597 Wolin, M.S. 2009. Reactive oxygen species and the control of vascular function. *Am. J. Physiol.*
598 *Heart. Circ. Physiol.* **296**(3): H539–H549.

599

600 Wu, G., Fang, Y.Z., Yang, S., Lupton, J.R., Turner, N.D. 2004. Glutathione metabolism and its
601 implications for health. *J. Nutr.* **134**(3): 489-492.

602

603 Yang, R.L., Shi, Y.H., Hao, G., Li, W., Le, G.W. 2008. Increasing oxidative stress with
604 progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic
605 index. *J. Clin. Biochem. Nutr.* **43**(3): 154–158.

606

|

607

608

|

609

TABLES

610

611 **Table 1.** Anthropometric and biochemical parameters of the normal weight and overweight612 group¹

	Normal weight group		Overweight group	
	M	F	M	F
Number of participants	16	32	16	32
General characteristics				
Age (years)	34.3±6.2	37.7±6.1	37.9±6.3	39.3±6.0
BMI (kg/m ²)	23.1±2.2	21.4±2.0	29.3±2.9***	29.5±2.7***
WC (cm)	84±7	72±5	100±6***	91±7***
Weight (kg)	75.9±9.4	60.1±6.1	95.6±8.2***	80.9±9.3***
Body fat (%)	15±5	24±5	24±3***	39±3***
SBP (mmHg)	131±14	118±14	139±19	121±15
DBP (mmHg)	74±16	69±10	79±10	74±5*
RMR (kcal/day)	1605±355	1387±244	1908±240**	1453±295
Biochemical parameters				
Fasting glucose (mmol/L)	5.2±0.5	5.0±0.4	5.6±0.3*	5.0±0.4
Fasting insulin (unit)	5.4±1.4	5.5±1.8	10.8±5.7***	8.4±3.2***
HOMA-IR	1.3±0.4	1.2±0.5	2.7±1.5***	1.9±0.8***
TAG (mmol/L)	1.1±0.8	0.9±0.3	1.7±0.8*	1.2±0.7**
Total cholesterol (mmol/L)	4.9±1.0	5.0±0.8	5.7±1.3	5.5±1.1
HDL-cholesterol (mmol/L)	1.4±0.3	1.6±0.3	1.2±0.2*	1.4±0.3*
LDL-cholesterol (mmol/L)	3.1±0.9	3.1±0.6	3.8±1.2	3.5±0.9*
CRP (mg/L)	1.1±1.1	0.7±0.7	1.8±1.5	3.6±3.4***

|

TNF- α (pg/L)	2.0 \pm 1.6	2.0 \pm 1.6	5.5 \pm 3.3**	5.1 \pm 3.4***
IL-6 (pg/L)	2.6 \pm 1.2	2.8 \pm 0.8	3.2 \pm 0.9	3.3 \pm 0.9
Cysteine (μ mol/L)	1.33 \pm 1.21	0.31 \pm 0.28	5.40 \pm 5.21***	3.94 \pm 3.64***
Lifestyle parameters				
MetS (n, %) ²	0 (0)	0 (0)	7 (43.8)***	4 (12.5)***
FI	101 \pm 13	111 \pm 15	82 \pm 18*	83 \pm 15***
Physical activity (min/week)	214 \pm 211	168 \pm 117	89 \pm 79*	122 \pm 82*
Current smokers (n, %)	1 (6.3)	5 (15.6)	1 (6.3)	3 (9.4)
Dietary parameters – nutrient intakes				
Proteins (g/day)	88 \pm 25	73 \pm 25	110 \pm 39	77 \pm 28
Carbohydrates (g/day)	279 \pm 80	227 \pm 69	245 \pm 93	247 \pm 102
Dietary fiber (g/day)	23 \pm 8	22 \pm 11	20 \pm 12	24 \pm 16
Fatty acids (g/day)	92 \pm 26	71 \pm 26	94 \pm 30	70 \pm 23
Saturated FAs (g/day)	29 \pm 10	22 \pm 9	33 \pm 14	23 \pm 9
Monounsaturated FAs (g/day)	26 \pm 14	20 \pm 9	24 \pm 12	20 \pm 8
Polyunsaturated FAs (g/day)	13 \pm 6	10 \pm 4	13 \pm 6	10 \pm 5
Vitamin C (mg/day)	121 \pm 90	145 \pm 70	67 \pm 38*	116 \pm 60
Folic acid (μ g/L)	5.92 \pm 2.54	6.70 \pm 2.89	5.71 \pm 1.64	7.32 \pm 2.62

613 **Note:** ¹All values are mean \pm SD. M, male; F, female; BMI, body mass index; WC, waist
614 circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; RMR, resting
615 metabolic rate; HOMA-IR, homeostasis model assessment for insulin resistance; HDL, high
616 density lipoproteins; LDL, low density lipoproteins; CRP, reactive protein C; TNF, tumor
617 necrosis factor; IL, interleukin; FI, physical fitness; FA, fatty acid; TAG, triacylglycerols.
618 ²MetS, metabolic syndrome. Components of the MetS are hypertriglyceridemia (\geq 1.7 mmol/L),
619 HDL levels ($<$ 1mmol/L in men and $<$ 1.3 mmol/L in women), large waist circumference (\geq 94

620 cm in men and ≥ 80 cm in women), elevated blood pressure (systolic ≥ 130 mmHg and/or
621 diastolic ≥ 85 mmHg) and elevated plasma glucose (≥ 5.6 mmol/L). Subject, identified as MetS,
622 has 3 or more components of the MetS.

623 Comparisons of physical, biochemical, nutritional, and other characteristics between two
624 groups (for males and females separately) were completed using one-factor analysis of the
625 variance. A chi square (χ^2) was used to investigate whether distributions of categorical variables
626 differ from one another (MetS (%), smokers (%)). The mean difference is significant at the 0.05
627 level; *** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$

628

629

630 **Table 2.** Energy value of food group of the normal weight and overweight participants ¹

gender	Normal weight group		Overweight group	
	M	F	M	F
Number of participants	16	32	16	32
Milk and milk products (kcal/day)	319±171	233±110	269±141	225±139
Vegetable (kcal/day)	75±62	46±41	33±22*	53±45
Fruit (kcal/day)	127±121	143±111	76±72	137±75
Starchy food (kcal/day)	722±203	528±155	658±258	617±323
Meat and meat products (kcal/day)	349±145	280±135	571±277*	364±147*
Fat and fatty food (kcal/day)	529±207	396±163	518±233	403±172
Sugars (kcal/day)	199±136	161±125	165±147	175±206

631 **Note:** ¹All values are mean ± SD. M, male; F, female.632 Comparison of nutritional characteristics between two groups (for males and females
633 separately) were completed with using one-factor analysis of the variance. **P* < 0.05

634

635

636

637 **Table 3.** Pearson correlation coefficients of total antioxidant capacity measure to age, selected
 638 anthropometric, biochemical, and blood pressure characteristic in men and women

	Men	Women
Variable	TAC	
	r (P)	r (P)
Age (years)	0.296 (0.204)	0.066 (0.653)
Body mass (kg)	0.359 (0.101)	0.438 (<0.001)
BMI (kg·m ⁻²)	0.627 (0.003)	0.463 (0.012)
WC (cm)	0.444 (0.050)	0.335 (0.024)
BF (%)	0.564 (0.006)	0.419 (0.016)
SBP (mmHg)	0.090 (0.706)	0.116 (0.698)
DBP (mmHg)	0.155 (0.513)	0.187 (0.376)
FI	-0.237 (0.360)	-0.112 (0.372)
Glucose (mmol/L)	0.454 (0.044)	0.153 (0.120)
Cholesterol (mmol/L)	0.258 (0.271)	0.048 (0.744)
HDL (mmol/L)	-0.139 (0.558)	-0.143 (0.326)
LDL (mmol/L)	0.216 (0.359)	0.132 (0.320)
TAG (mmol/L)	0.387 (0.075)	0.280 (0.026)
CRP (mg/L)	0.397 (0.067)	0.258 (0.041)
Insulin (μU/mL)	0.529 (0.011)	0.202 (0.116)
HOMA-IR	0.545 (0.009)	0.172 (0.182)
Cysteine (μmol/L)	0.489 (0.029)	0.122 (0.345)

639 **Note:** BMI, body mass index; WC, waist circumference; BF, body fat; SBP, systolic blood
 640 pressure; DBP, diastolic blood pressure; FI, fitness index; HDL, high density lipoprotein; LDL,

641 low density lipoprotein; TAG, triacylglycerols; CRP, C-reactive protein; HOMA-IR,
642 homeostatic model assessment of insulin resistance.

643 The statistically significant association is at $P < 0.05$ (bold)

644

645 **Table 4.** Partial correlation coefficients of total antioxidant capacity measure to selected
 646 anthropometric and biochemical parameters after adjustment for age, physical activity, total
 647 energy intake, smoking, and common cardiometabolic risk factors (blood pressure, glucose,
 648 LDL/HDL-cholesterol, TAG) in men and women

	Men	Women
Variable	TAC (after adjustments)	
	r (P)	r (P)
BMI (kg·m⁻²)	0.453 (0.033)	0.416 (0.002)
BF (%)	0.344 (0.046)	0.321 (0.017)
CRP (mg/L)	0.298 (0.082)	0.249 (0.051)
Cysteine (μmol/L)	0.530 (0.032)	0.147 (0.287)

649 **Note:** BMI, body mass index; WC, waist circumference; CRP, C-reactive protein.

650 The statistically significant association is at $P < 0.05$ (bold)

651

652

653 **FIGURE LEGENDS**

654

655 **Fig. 1** Total antioxidant capacity in serum, expressed as nanomoles of ascorbic acids per μL of
656 serum, in the normal weight group in comparison to the overweight participants, in both men
657 and women was analyzed by an independent-sample t-test; a *P* value of less than 0.05 was
658 considered statistically significant.

659

660 **Fig. 2** Pearson's correlation analyses were performed to detect correlations between total
661 antioxidant capacity in serum, expressed as nanomoles of ascorbic acids per μL of serum and
662 selected anthropometric characteristics (body mass index (A) and body fat (B)) in women (1;
663 green lines and green spots) and men (0; blue lines and blue spots)


664

665 **FIGURES**

666

667 >> **Fig. 1**

668



669


670

671

672

673 >> Fig. 2 (A, B)

674



675